Seizure outcome trajectories in a well‐defined cohort of newly diagnosed juvenile myoclonic epilepsy patients

2021 ◽  
Author(s):  
Emanuele Cerulli Irelli ◽  
Alessandra Morano ◽  
Biagio Orlando ◽  
Enrico M. Salamone ◽  
Martina Fanella ◽  
...  
Keyword(s):  
Juvenile Myoclonic Epilepsy ◽  
Myoclonic Epilepsy ◽  
Seizure Outcome ◽  
Newly Diagnosed

scholarly journals Predictors for long-term seizure outcome in juvenile myoclonic epilepsy: 25-63 years of follow-up

Epilepsia ◽  
2012 ◽  
Vol 53 (8) ◽  
pp. 1379-1386 ◽  
Author(s):  
Julia Geithner ◽  
Felix Schneider ◽  
Zhong Wang ◽  
Julia Berneiser ◽  
Rosemarie Herzer ◽  
...  
Keyword(s):  
Juvenile Myoclonic Epilepsy ◽  
Myoclonic Epilepsy ◽  
Seizure Outcome

scholarly journals Topiramate for the treatment of juvenile myoclonic epilepsy

2005 ◽  
Vol 63 (3b) ◽  
pp. 733-737 ◽  
Author(s):  
Patrícia da Silva Sousa ◽  
Gerardo Maria de Araújo Filho ◽  
Eliana Garzon ◽  
Américo C. Sakamoto ◽  
Elza Márcia T. Yacubian
Keyword(s):  
Side Effects ◽  
Seizure Control ◽  
Juvenile Myoclonic Epilepsy ◽  
Myoclonic Epilepsy ◽  
First Year ◽  
Newly Diagnosed ◽  
Seizure Reduction ◽  
Subject Choice ◽  
Clonic Seizures

OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of topiramate (TPM) in juvenile myoclonic epilepsy (JME). METHOD: We assessed seizure control and adverse effects of TPM in 22 patients (18 females) aged 13 to 53 years. Target TPM dosage was up to 200 mg/day. The patients were subdivided into 3 groups: those treated with seizure control plus side effects (n=4); treated with non-controlled seizures (n=15) and with JME newly diagnosed (n=3). RESULTS: Sixteen patients completed the first year of the follow-up. Generalized tonic-clonic seizures were completely controlled in 10 (62.5%); more than 50% of reduction in 4 (25.0%) and less than 50% in 2 (12.5%). Myoclonia were controlled in 11 (68.8%) and persisted in 5 (31.2%) patients. Absence seizures were present in 5 (22.7%) of whom 2 (9.0%) showed more than 50% of seizure reduction while 3 (13.6%) presented worsening. Discontinuations were due to inadequate seizure control and adverse events (N=4), low compliance and loss of follow-up (N=2) and subject choice (N=1). CONCLUSION: TPM showed to be an effective and well-tolerated drug in the treatment of JME. Although frequently observed, TPM side effects were tolerable and the drug could be maintained in the majority of patients.

scholarly journals Seizure outcome in 175 patients with juvenile myoclonic epilepsy – A long-term observational study

2014 ◽  
Vol 108 (10) ◽  
pp. 1817-1824 ◽  
Author(s):  
Julia Höfler ◽  
Iris Unterberger ◽  
Judith Dobesberger ◽  
Giorgi Kuchukhidze ◽  
Gerald Walser ◽  
...  
Keyword(s):  
Observational Study ◽  
Juvenile Myoclonic Epilepsy ◽  
Myoclonic Epilepsy ◽  
Seizure Outcome

Prognosis of juvenile myoclonic epilepsy 45 years after onset: Seizure outcome and predictors

Neurology ◽  
2013 ◽  
Vol 81 (24) ◽  
pp. 2128-2133 ◽  
Author(s):  
P. Senf ◽  
B. Schmitz ◽  
M. Holtkamp ◽  
D. Janz
Keyword(s):  
Juvenile Myoclonic Epilepsy ◽  
Myoclonic Epilepsy ◽  
Seizure Outcome ◽  
Onset Seizure

Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents

2008 ◽  
Vol 50 (1) ◽  
pp. 29-32 ◽  
Author(s):  
Alberto Verrotti ◽  
Caterina Cerminara ◽  
Giangennaro Coppola ◽  
Emilio Franzoni ◽  
Pasquale Parisi ◽  
...  
Keyword(s):  
Juvenile Myoclonic Epilepsy ◽  
Myoclonic Epilepsy ◽  
Newly Diagnosed ◽  
Term Efficacy

Predictive value of EFHC1 variants for the long-term seizure outcome in juvenile myoclonic epilepsy

2015 ◽  
Vol 44 ◽  
pp. 61-66 ◽  
Author(s):  
Felix von Podewils ◽  
Victoria Kowoll ◽  
Winnie Schroeder ◽  
Julia Geithner ◽  
Zhong I. Wang ◽  
...  
Keyword(s):  
Predictive Value ◽  
Juvenile Myoclonic Epilepsy ◽  
Myoclonic Epilepsy ◽  
Seizure Outcome
Sign in / Sign up

Export Citation Format

Share Document